Abstract:CD19 antigen is a major target for human B cell malignancies. Many studies have shown that the antibodies recognizing this antigen hold clinical therapeutic potential, while CD19 antibody of mouse origin requires genetic engineering to reduce the potential side effects of the antibody for their clinical use. There are many clones of CD19 antibodies available with different subclasses of immunoglobulin. IgM type antibody holds a high affinity and high complement activating capacities facilitating the targeting efficacy when it is used in targeting therapy. However, engineering the murine IgM antibody into a functional humanized antibody remains a challenge. The aim of this study was to construct a chimeric antibody composed of a CD19 specific murine IgM antibody 2E8 single-chain antibody fragment (scFv) and human IgG1 Fc region, which was named 2E8scFv-Fc or Hm2E8b. The function and the biological activities of this engineered antibody were characterized using a variety of approaches including cellular, immunological, flow cytometric, and molecular biological approaches. After switching from IgM- to IgG-like type antibody, Hm2E8b retained full antigen-binding activity to membrane CD19 antigen as its parental antibody 2E8, and the immune effector function analysis revealed that it could mediate complement-dependent cytotoxicity (CDC) to kill the target cells via IgG1 Fc domain. The yield of the engineered antibody Hm2E8b in the supernatant was 13.3 μg/mL expressed and secreted in the CHO cell system, which reached the secretory quantity of a regular mouse hybridoma cells. Our conclusion is that the IgM type of CD19 mouse antibody can be successfully engineered into an IgG1 type human-mouse chimeric antibody with similar affinity and biological activity. The yield of the Hm2E8b expression and secretion in CHO cell system was adequate to facilitate further development for therapeutic purpose.

A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Construction and Expression of a Human/mouse Chimeric CD19 Monoclonal Antibody: Successful Modification of a Murine IgM to a Chimeric IgG.

Generation and Characterisation of Rabbit Monoclonal Antibodies Against the Native Cell Surface Antigens of Embryonic Stem Cells.

ESTABLISHMENT OF FOUR HYBRIDOMA CELL LINES SECRETING ANTI-HUMAN IGA MCABS

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Cloning and Sequencing of the Light Chain Variable Region from NS-1 Myeloma.

Production of Anti-Tumor Human Monoclonal Antibodies Using Different Approaches.

Continuous cultures of fused cells secreting antibody of predefined specificity

Production of Antitumor Human Monoclonal Antibodies by Human-Human or Mouse-Human Hybridoma

[Cloning and Sequencing of VL and VH Genes from a Novel Clone ZCH-7-2F9 of Anti-Hcd14 Monoclonal Antibody].

Identification of Two Aberrant Transcripts Derived from A Hybridoma with Amplification of Functional Immunoglobulin Variable Genes

Polyclonal Hyper-Ige Mouse Model Reveals Mechanistic Insights into Antibody Class Switch Recombination.

Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production.

A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

Cloning of 3H11 Mab Variable Region Gene and Expression of 3H11 Human-Mouse Chimeric Light Chain.

Affinity Purification of Mab from Serum-Containing Hybridoma Culture Supernatant Through a Novel Nanobody That Discriminates Mouse IgG from Bovine IgG by Recognizing the Mouse Kappa Constant Region (Mck)

[Cloning and Expression of Human Anti-Colonic Cancer Single-Chain Fv Fragment].

Developing a workflow for the isolation of hybridoma cells producing fully human antigen-specific antibodies using a surface IgG detection method

Expression Cloning of Antibodies from Single Human B Cells